Login
E-mail
Password
Mostra password
Ricorda
Password dimenticata?
Iscriviti gratuitamente
Registrazione
Registrazione
Parametri
Parametri
Quotazioni dinamiche 
OFFON

NGM BIOPHARMACEUTICALS, INC.

(NGM)
RiassuntoQuotazioniGraficiNotizieRatingAgendaSocietÓFinanzaConsensusRevisioniDerivati 
RiassuntoTutte le notizieRaccomandazione analistiAltre lingueComunicati stampaPubblicazioni ufficialiNotizie del settore
Notizie in altre lingue su NGM BIOPHARMACEUTICALS, INC.
09/11NGM Bio to Participate in Upcoming Investor Conferences
04/11NGM BIOPHARMACEUTICALS: Q3 Earnings Snapshot
04/11NGM Bio Provides Business Highlights and Reports Third Quarter 2021 Financial Results -..
04/11NGM BIOPHARMACEUTICALS INC Management's Discussion and Analysis of Financial Condition..
04/11NGM Biopharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Mo..
04/11NGM BIOPHARMACEUTICALS INC: Results of Operations and Financial Condition (form 8-K)
04/11NGM Bio Provides Business Highlights and Reports Third Quarter 2021 Financial Results
16/09NGM BIOPHARMACEUTICALS: Bio Presents Preliminary Findings from Ongoing Phase 1a/1b Dose E..
16/09NGM Biopharmaceuticals, Inc. Presents Preliminary Findings from Ongoing Phase 1A/1B Dos..
13/09NGM BIOPHARMACEUTICALS: Stock Climbs After Raymond James Upgrade
23/08NGM BIOPHARMACEUTICALS: Developing NGM831 to Treat Cancer
23/08NGM BIOPHARMACEUTICALS: Bio Discloses Fourth Oncology Development Candidate, 831, an ILT3..
23/08NGM Biopharmaceuticals, Inc. Discloses Fourth Oncology Development Candidate, NGM831, a..
06/08NGM BIOPHARMACEUTICALS: Q2 Earnings Snapshot
05/08NGM BIOPHARMACEUTICALS: Management's Discussion and Analysis of Financial Condition and R..
05/08NGM BIOPHARMACEUTICALS INC: Results of Operations and Financial Condition (form 8-K)
05/08NGM BIOPHARMACEUTICALS: Bio Provides Business Highlights and Reports Second Quarter 2021 ..
05/08Ngm Biopharmaceuticals, Inc. Reports Earnings Results for the Second Quarter Ended June..
22/07NGM BIOPHARMACEUTICALS: Announces Completion of Enrollment in Phase 2 CATALINA Study of 6..
22/07NGM Announces Completion of Enrollment in Phase 2 CATALINA Study of NGM621 in Patients ..
07/07NGM BIOPHARMACEUTICALS: Doses First Patient in Study Evaluating Potential Cancer Drug
07/07NGM Bio Announces Initiation of Phase 1/2 Clinical Study of NGM707 for the Treatment of..
07/07NGM Biopharmaceuticals, Inc. Announces Initiation of Phase 1/2 Clinical Study of NGM707..
01/07NGM BIOPHARMACEUTICALS: Amends Partnership With Merck to Focus on Retinal, Cardiovascular..
01/07NGM BIOPHARMACEUTICALS: Amended and Restated Research Collaboration, Product Development ..
01/07NGM BIOPHARMACEUTICALS INC: Entry into a Material Definitive Agreement (form 8-K)
01/07NGM Amends Collaboration with Merck to Focus Primarily on Advancing Novel Medicines for..
10/06NGM BIOPHARMACEUTICALS INC: Submission of Matters to a Vote of Security Holders (form 8-K..
07/06NGM Bio to Present at Two Upcoming Investor Conferences
26/05ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Aga..
25/05INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against ..
25/05TODAY ON WALL STREET: Tech stocks’ return as inflation fears ease
25/05TODAY'S ANALYST RECOMMENDATIONS: Deere, Endeavor, Just Eat, Royal Mail, Visa...
24/05Virgin Galactic, Ormat Technologies rise; Cimarex, NGM fall
24/05SECTOR UPDATE: Health Care Stocks Still Narrowly Higher in Late Regular-Hours Trade
24/05INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against NGM..
24/05UPDATE: NGM Bio Drops Aldafermin Liver Disease Drug After Trial Failure, Shares Slump 40%
24/05SECTOR UPDATE: Health Care Stocks Higher in Moderation
24/05NGM BIOPHARMACEUTICALS: to End Development of Liver Disease Drug Candidate After Clinical..
24/05NGM BIOPHARMACEUTICALS: Topline NASH Phase 2b ALPINE 2/3 Trial Results Presentation
24/05SECTOR UPDATE: Health Care Stocks Trade Higher Premarket Monday
24/05SECTOR UPDATE: Health Care
24/05NGM BIOPHARMACEUTICALS: Bio Says Study of Liver Disease Drug Candidate Aldafermin Failed ..
24/05NGM BIOPHARMACEUTICALS: Bio Reports Topline Results from 24-Week Phase 2b ALPINE 2/3 Stud..
24/05NGM BIOPHARMACEUTICALS INC: Other Events, Financial Statements and Exhibits (form 8-K)
24/05NGM Biopharmaceuticals, Inc. Reports Topline Results from 24-Week Phase 2B Alpine 2/3 S..
24/05NGM Bio Reports Topline Results from 24-Week Phase 2b ALPINE 2/3 Study of Aldafermin in..
24/05NGM Bio to Host Conference Call to Discuss Topline Results from 24-Week Phase 2b ALPINE..
07/05NGM BIOPHARMACEUTICALS: Q1 Earnings Snapshot
06/05NGM BIOPHARMACEUTICALS: Management's Discussion and Analysis of Financial Condition and R..
06/05NGM BIOPHARMACEUTICALS INC: Results of Operations and Financial Condition (form 8-K)
06/05NGM Bio Provides Business Highlights and Reports First Quarter 2021 Financial Results
06/05Ngm Biopharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March..
28/04NGM BIOPHARMACEUTICALS INC: Change in Directors or Principal Officers, Other Events, Fina..
28/04NGM Biopharmaceuticals, Inc. Announces Director Resignations
28/04NGM Announces Nomination of Roger M. Perlmutter for Election to Its Board of Directors
15/03NGM BIOPHARMACEUTICALS: Management's Discussion and Analysis of Financial Condition and R..
15/03NGM BIOPHARMACEUTICALS INC: Entry into a Material Definitive Agreement, Financial Stateme..
07/03Certain Common Stock of NGM Biopharmaceuticals, Inc. are subject to a Lock-Up Agreement..
07/03Certain Stock Options of NGM Biopharmaceuticals, Inc. are subject to a Lock-Up Agreemen..
05/03NGM BIOPHARMACEUTICALS: Q4 Earnings Snapshot
04/03Ngm Biopharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended Dece..
04/03NGM Bio Provides Business Highlights and Reports Fourth Quarter and Full Year 2020 Fina..
02/03NGM BIOPHARMACEUTICALS: Biopharma Starts Phase 1b Study of 120 in Patients with Metastati..
02/03NGM BIOPHARMACEUTICALS: Bio Initiates Expansion of Ongoing Phase 1b Proof-of-Concept Stud..
02/03NGM Biopharmaceuticals, Inc. Initiates Expansion of Ongoing Phase 1B Proof-Of-Concept S..
25/02NGM BIOPHARMACEUTICALS: Bio to Present at the Cowen 41st Annual Health Care Conference
24/02Geographic Atrophy Treatment Market is expected to grow steeply with a CAGR of ~30%, co..
10/02NGM BIOPHARMACEUTICALS: Bio Announces Upcoming Oral Presentation of Phase 1 Study of 621 ..
09/02NGM BIOPHARMACEUTICALS: Bio Announces Upcoming Oral Presentation of Phase 1 Study of 621 ..
12/01NGM Bio Outlines 2021 Strategic Priorities Across Its Three Therapeutic Area Portfolios..
06/01NGM BIOPHARMACEUTICALS INC: Results of Operations and Financial Condition, Other Events, ..
06/01NGM BIOPHARMACEUTICALS: Prices $125 Million Public Offering
06/01NGM Bio Announces Pricing of Upsized $125.0 Million Public Offering of Common Stock
05/01SECTOR UPDATE: Health Care Stocks Ending Near Tuesday Session Highs
1  2  3Pross.
Prossimo evento su NGM BIOPHARMACEUTICALS, INC.
01/12/21